Pancreatic cancer used to be thought of as a disease of old age. For decades, doctors – including me – were trained to think of it as something that mainly struck people in their 60s and beyond. The ...

Pancreatic cancer continues to be a devastating disease, with an overall 5-year survival rate of around 13%. Accounting for about 3% of all cancers, it is the third leading cause of cancer death in ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

Scientists have uncovered a hidden partnership between pancreatic cancer and the nervous system. Support cells in the pancreas lure nerve fibers, which then release signals that accelerate early ...

FDA approved Optune Pax for locally advanced pancreatic cancer with gemcitabine/nab-paclitaxel, marking the first new modality in decades for this nonresectable ...

Current drugs for pancreatic cancer lose effectiveness within months because the tumor becomes resistant. Now, a group from Spain's National Cancer Research Centre (CNIO) has been able to avoid the ...

Researchers in Spain have developed a new therapy protocol that could revolutionize the treatment of pancreatic cancer. Notoriously aggressive and difficult to treat, pancreatic cancer is rarely ...

The UK warned some patients have died of severe inflammation of the pancreas linked to obesity and diabetes drugs such as Eli Lilly & Co.’s Mounjaro and Novo Nordisk A/S’s Wegovy. Though the worst ...

Spanish scientists say they have developed a potential breakthrough cure for treating pancreatic cancer, but the new therapy isn't ready for human use yet. Pancreatic cancer forms tumors in the ...

Pancreatic cancer treatment relies on surgery, chemotherapy, and radiation, with surgery for non-metastatic, technically resectable tumors. Advances in chemotherapy, neoadjuvant approaches, and ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial. The TACTOPS trial, which ...